Personalized medicine and oncology: A commentary and key questions

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.16, Iss.3, 2010-07, pp. : 197-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of recent IP caselaw on biomarkers and personalized medicine

By Gass David A

Journal of Commercial Biotechnology, Vol. 17, Iss. 2, 2011-05 ,pp. : 191-194

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Personalized medicine: revolutionizing drug discovery and patient care

By Ginsburg G.S. McCarthy J.J.

Trends in Biotechnology, Vol. 19, Iss. 12, 2001-12 ,pp. : 491-496

Elsevier

Access to resources Recommend Favorite

Key word index

Bioseparation, Vol. 6, Iss. 6, 1996-01 ,pp. : 389-390

Springer Publishing Company

Access to resources Recommend Favorite

Antisense therapy in clinical oncology: Preclinical and clinical experiences

By Tamm Ingo Wagner Mandy

Molecular Biotechnology, Vol. 33, Iss. 3, 2006-07 ,pp. : 221-238

Humana Press, Inc

Access to resources Recommend Favorite

Proteomics of multiprotein complexes: answering fundamental questions in neuroscience

By Grant S.G.N. Husi H.

Trends in Biotechnology, Vol. 19, Iss. 10, 2001-10 ,pp. : 49-54

Elsevier

Access to resources Recommend Favorite